Accelerate everything when you have the best intel
We started Sonrai in response to a growing need within precision medicine for a platform that could integrate large-scale multi-omic data types and generate significant insights and hypotheses, leading to the discovery of novel therapies and biomarkers. Our guiding light is to improve diagnosis and treatment for patients worldwide.
Our Mission is to Empower Precision Medicine Through AI Innovation
We simplify complicated, difficult, or expensive engineering, data science, and bioinformatics tasks to empower healthcare organisations to make the most of their data with minimal required effort or expertise. We do this via our Discovery Platform, coupled with our team’s experience and expert knowledge, who work hand-in-hand with our clients to help them achieve their vision.
In 2018, Queen’s University Belfast Bioinformatics Researchers Dr Darragh McArt and Dr Deva Senevirathne realised that there was an urgent need to enhance and accelerate healthcare data analysis to develop new and better treatments for disease.
From this, a company was born: Sonrai Analytics. It was founded on the knowledge that AI and ML is the only way to find the hidden value in big data.
Today, Sonrai is empowering data scientists, biologists, translational researchers and business leaders around the world to identify high-value biomarkers, validate state-of-the-art algorithms and bring new drugs to market much faster.
We have come along way in the last few years. We have been able to adapt and learn from every meeting and client interaction, because of our ability to listen to and understand our customers.
While presenting their solution framework at an event, a leader from a Boston-based biotech grasps the opportunity. That biotech became our first customer. Sonrai Analytics is born.
Sonrai raises Seed funding to develop production-grade Cloud Data Discovery tools. We partner with Roche and QUB in a £7m consortium to improve cancer outcomes by developing Deep-Learning Research Algorithms with Shared IP.
We doubled our workforce in 2020 and version 1 of Sonrai went live. R&D and gaining greater customer feedback takes precedent.
Sonrai expands its Senior Leadership, R&D and product development resulting in an NHS contract worth £2M to lead on producing Clinical Algorithms that directly support Digital Pathologists and improve patient outcomes.
Sonrai announces £2.175m 'Seed-Plus' Funding Round to accelerate international growth
Talk to us
We don’t talk at you. We listen to your challenges and only show you what you’ll value most.